articleTop 1% cited

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Nature Medicine · 2013 · Vol. 19(2) · pp. 202–208

Andrew J. Souers✉(AbbVie (United States))Joel Johansson(AbbVie (United States))Erwin R. Boghaert(AbbVie (United States))Scott Ackler(AbbVie (United States))Nathaniel D. Catron(AbbVie (United States))Jun Chen(AbbVie (United States))Brian D. Dayton(AbbVie (United States))Hong Ding(AbbVie (United States))Sari H. Enschede(AbbVie (United States))Wayne J. FairbrotherDavid C.S. Huang(University of Melbourne)S.G. HymowitzSha Jin(AbbVie (United States))Seong Lin Khaw(Walter and Eliza Hall Institute of Medical Research)Peter Kovar(AbbVie (United States))Lloyd T. Lam(AbbVie (United States))Jackie LeeHeather MaeckerKennan C. Marsh(AbbVie (United States))Kylie D. Mason(University of Melbourne)Michael J. Mitten(AbbVie (United States))Paul Nimmer(AbbVie (United States))Anatol Oleksijew(AbbVie (United States))Chang H. Park(AbbVie (United States))Cheol‐Min Park(AbbVie (United States))Darren C. Phillips(AbbVie (United States))Andrew W. Roberts(The Royal Melbourne Hospital)Deepak SampathJohn F. Seymour(University of Melbourne)Morey L. Smith(AbbVie (United States))Gerard M. Sullivan(AbbVie (United States))Stephen K. Tahir(AbbVie (United States))Chris Tse(AbbVie (United States))Michael Wendt(AbbVie (United States))Xiao Yu(AbbVie (United States))John Xue(AbbVie (United States))Haichao Zhang(AbbVie (United States))Rod Humerickhouse(AbbVie (United States))Saul H. Rosenberg(AbbVie (United States))Steven W. Elmore(AbbVie (United States))

View via DOI Publisher page

Chronic Lymphocytic Leukemia Research Cell death mechanisms and regulation Acute Lymphoblastic Leukemia researchChronic lymphocytic leukemiaCancer researchApoptosisVenetoclaxIn vivoBcl-2 familyLymphomaLeukemiaCancerPharmacology

MeSH terms

Aniline CompoundsAnimalsAntineoplastic AgentsBlood PlateletsCell SurvivalDogsFemaleHeLa CellsHumansSulfonamidesMice, SCIDApoptosisBridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-bcl-2Hematologic Neoplasms

Citations

2,976

FWCI

107.60

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)